| Primary |
| Convulsion |
24.7% |
| Product Used For Unknown Indication |
18.7% |
| Lennox-gastaut Syndrome |
15.7% |
| Epilepsy |
10.9% |
| Constipation |
3.7% |
| Surgery |
3.4% |
| Insomnia |
2.6% |
| Pain |
2.6% |
| Anxiety |
2.2% |
| Nutritional Supplementation |
2.2% |
| Attention Deficit/hyperactivity Disorder |
1.9% |
| Pyrexia |
1.9% |
| Sleep Disorder |
1.9% |
| Generalised Oedema |
1.5% |
| Vitamin Supplementation |
1.5% |
| Asthma |
1.1% |
| Pneumonia |
1.1% |
| Abnormal Behaviour |
0.7% |
| Bronchial Hyperreactivity |
0.7% |
| Flatulence |
0.7% |
|
| Convulsion |
28.6% |
| Pneumonia |
14.3% |
| Status Epilepticus |
8.6% |
| Dehydration |
2.9% |
| Encephalopathy |
2.9% |
| Exposure During Pregnancy |
2.9% |
| Feeding Disorder |
2.9% |
| Gastrooesophageal Reflux Disease |
2.9% |
| Grand Mal Convulsion |
2.9% |
| Haematemesis |
2.9% |
| Hepatic Enzyme Increased |
2.9% |
| Hypokalaemia |
2.9% |
| Influenza |
2.9% |
| Laceration |
2.9% |
| Lennox-gastaut Syndrome |
2.9% |
| Lethargy |
2.9% |
| Overdose |
2.9% |
| Petit Mal Epilepsy |
2.9% |
| Pneumonia Aspiration |
2.9% |
| Pneumonia Viral |
2.9% |
|
| Secondary |
| Epilepsy |
31.3% |
| Product Used For Unknown Indication |
18.3% |
| Convulsion |
11.5% |
| Drug Use For Unknown Indication |
8.1% |
| Lennox-gastaut Syndrome |
5.6% |
| Infantile Spasms |
4.8% |
| Drug Exposure During Pregnancy |
3.4% |
| Status Epilepticus |
3.4% |
| Foetal Exposure During Pregnancy |
2.0% |
| Grand Mal Convulsion |
1.9% |
| Partial Seizures |
1.6% |
| Myoclonic Epilepsy |
1.3% |
| Temporal Lobe Epilepsy |
1.1% |
| Pneumonia Mycoplasmal |
1.0% |
| Tonic Convulsion |
1.0% |
| Atonic Seizures |
1.0% |
| Anxiety |
0.8% |
| Thrombosis Prophylaxis |
0.7% |
| Mental Retardation |
0.6% |
| Sleep Disorder |
0.6% |
|
| Drug Ineffective |
8.6% |
| Convulsion |
7.5% |
| Somnolence |
7.5% |
| Status Epilepticus |
7.5% |
| Maternal Exposure During Pregnancy |
6.3% |
| Stevens-johnson Syndrome |
6.3% |
| Hip Dysplasia |
6.0% |
| Foetal Exposure During Pregnancy |
5.6% |
| Toxic Epidermal Necrolysis |
5.2% |
| Vomiting |
5.2% |
| Drug Exposure During Pregnancy |
4.5% |
| Hypospadias |
4.5% |
| Maternal Drugs Affecting Foetus |
3.7% |
| Toxicity To Various Agents |
3.7% |
| Spina Bifida |
3.4% |
| Congenital Arterial Malformation |
3.0% |
| Drug Interaction |
3.0% |
| Petit Mal Epilepsy |
3.0% |
| Pneumonia |
3.0% |
| Suicide Attempt |
2.6% |
|
| Concomitant |
| Epilepsy |
41.0% |
| Product Used For Unknown Indication |
14.1% |
| Convulsion |
8.5% |
| Drug Use For Unknown Indication |
8.3% |
| Grand Mal Convulsion |
4.3% |
| Myoclonic Epilepsy |
4.2% |
| Hiv Infection |
3.3% |
| Partial Seizures |
2.9% |
| Temporal Lobe Epilepsy |
1.7% |
| Complex Partial Seizures |
1.5% |
| Status Epilepticus |
1.3% |
| Glioblastoma |
1.3% |
| Convulsion Prophylaxis |
1.2% |
| Prophylaxis |
1.1% |
| Pneumonia Mycoplasmal |
1.1% |
| Acquired Immunodeficiency Syndrome |
1.0% |
| Depression |
0.9% |
| Ill-defined Disorder |
0.8% |
| Infection Prophylaxis |
0.8% |
| Antifungal Prophylaxis |
0.7% |
|
| Epilepsy |
13.1% |
| Convulsion |
12.1% |
| Somnolence |
8.2% |
| Status Epilepticus |
7.5% |
| Pyrexia |
6.1% |
| Thrombocytopenia |
5.8% |
| Vomiting |
5.6% |
| Weight Decreased |
5.6% |
| Premature Labour |
4.4% |
| Pancreatitis |
3.9% |
| Sepsis |
3.9% |
| Toxicity To Various Agents |
3.1% |
| Tracheo-oesophageal Fistula |
3.1% |
| Drug Ineffective |
2.7% |
| Grand Mal Convulsion |
2.7% |
| Wheezing |
2.7% |
| Pregnancy |
2.4% |
| Psychotic Disorder |
2.4% |
| Rash |
2.4% |
| Vesicoureteric Reflux |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
17.9% |
| Convulsion |
13.8% |
| Epilepsy |
13.8% |
| Convulsion Prophylaxis |
13.0% |
| Antiviral Treatment |
9.8% |
| Osteoporosis |
8.1% |
| Hypertension |
4.9% |
| Grand Mal Convulsion |
3.3% |
| Pain |
3.3% |
| Myoclonic Epilepsy |
2.4% |
| Product Used For Unknown Indication |
2.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.4% |
| Drop Attacks |
1.6% |
| Post-traumatic Epilepsy |
1.6% |
| Fungal Infection |
0.8% |
| Learning Disability |
0.8% |
|
| Drug Interaction |
26.9% |
| Sweat Gland Disorder |
15.4% |
| Asthenia |
11.5% |
| Weight Decreased |
11.5% |
| Epilepsy |
7.7% |
| Ataxia |
3.8% |
| Drug Toxicity |
3.8% |
| Fall |
3.8% |
| Lethargy |
3.8% |
| Movement Disorder |
3.8% |
| Myoclonic Epilepsy |
3.8% |
| Transaminases Increased |
3.8% |
|
